BET Protein Inhibitor Apabetalone Suppresses Inflammatory Hyperactivation of Monocytes From Patients With Cardiovascular Disease and Type 2 Diabetes

被引：0
|
作者：
Wasiak, Sylwia
Dzobo, Kim
Rakai, Brooke
Kaiser, Yannick
Versloot, Miranda
Bahjat, Mahnoush
Stotz, Stephanie
Fu, Li
Sweeney, Michael
Johansson, Jan
Wong, Norman
Stroes, Erik
Kroon, Jeffrey
Kulikowski, Ewelina
机构：
来源：
CIRCULATION | 2020年 / 142卷
关键词：
D O I：
10.1161/circ.142.suppl_3.14127
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
A14127
引用
收藏
页数：2
相关论文
共 50 条
  • [11] Reduction in the Risk of Major Adverse Cardiovascular Events With Apabetalone, a Bet Protein Inhibitor, in Patients With Recent Acute Coronary Syndrome and Type 2 Diabetes According to Insulin Treatment: Analysis of the Betonmace Trial
    Schwartz, Gregory G.
    Nicholls, Stephen J.
    Ginsberg, Henry
    Johansson, Jan
    Kalantar-Zadeh, Kamyar
    Kulikowski, Ewelina
    Toth, Peter P.
    Wong, Norman
    Sweeney, Michael
    Ray, Kausik K.
    [J]. CIRCULATION, 2020, 142
  • [12] Reduction in the risk of major adverse cardiovascular events with the BET protein inhibitor apabetalone in patients with recent acute coronary syndrome, type 2 diabetes, and moderate to high likelihood of non-alcoholic fatty liver disease
    Toth, Peter P.
    Schwartz, Gregory G.
    Nicholls, Stephen J.
    Khan, Aziz
    Szarek, Michael
    Ginsberg, Henry N.
    Johansson, Jan O.
    Kalantar-Zadeh, Kamyar
    Kulikowski, Ewelina
    Lebioda, Ken
    Wong, Norman C. W.
    Sweeney, Michael
    Ray, Kausik K.
    [J]. AMERICAN JOURNAL OF PREVENTIVE CARDIOLOGY, 2022, 11
  • [13] Cardiovascular Evaluation of the Selective BET Inhibitor, Apabetalone, in ACS Patients With Diabetes: Baseline Characteristics of the BETonMACE CV Outcomes Study
    Ray, Kausik K.
    Nicholls, Stephen J.
    Sweeney, Mike
    Johansson, Jan O.
    Toth, Peter P.
    Ginsberg, Henry
    Kalantar-Zadeh, Kamyar
    Schwartz, Gregory G.
    [J]. CIRCULATION, 2018, 138
  • [14] Effect of selective BET protein inhibitor apabetalone on cardiovascular outcomes in patients with acute coronary syndrome and diabetes: Rationale, design, and baseline characteristics of the BETonMACE trial
    Ray, Kausik K.
    Nicholls, Stephen J.
    Ginsberg, Henry D.
    Johansson, Jan O.
    Kalantar-Zadeh, Kamyar
    Kulikowski, Ewelina
    Toth, Peter P.
    Wong, Norman
    Cummings, Jeffrey L.
    Sweeney, Michael
    Schwartz, Gregory G.
    [J]. AMERICAN HEART JOURNAL, 2019, 217 : 72 - 83
  • [15] APABETALONE, A CLINICAL STAGE BET INHIBITOR, REDUCES THE PRO-INFLAMMATORY RESPONSE IN PBMCS FROM FABRY DISEASE PATIENTS ON ERT THERAPY
    Fu, Li
    Wasiak, Sylwia
    Rakai, Brooke
    Stotz, Stephanie
    Wong, Norman
    Johansson, Jan
    Sweeney, Michael
    Mohan, Connie
    Khana, Aneal
    Kulikowski, Ewelina
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2020, 35 : 364 - 364
  • [16] Selective BET Protein Inhibition with Apabetalone and Cardiovascular Events: A Pooled Analysis of Trials in Patients with Coronary Artery Disease
    Nicholls, Stephen J.
    Ray, Kausik K.
    Johansson, Jan O.
    Gordon, Alan
    Sweeney, Michael
    Halliday, Chris
    Kulikowski, Ewelina
    Wong, Norman
    Kim, Susan W.
    Schwartz, Gregory G.
    [J]. AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS, 2018, 18 (02) : 109 - 115
  • [17] APABETALONE, A SELECTIVE BROMODOMAIN AND EXTRA-TERMINAL (BET) PROTEIN INHIBITOR, REDUCES SERUM FGF23 IN CARDIOVASCULAR DISEASE AND CHRONIC KIDNEY DISEASE PATIENTS
    Kalantar-Zadeh, Kamyar
    Zoccali, Carmine
    Beddhu, Srinivasan
    Brandenburg, Vincent
    Haarhaus, Mathias
    Tonelli, Marcello
    Khan, Aziz
    Halliday, Christopher
    Lebioda, Ken
    Johansson, Jan O.
    Sweeney, Michael
    Wong, Norman C. W.
    Kulikowski, Ewelina
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2019, 34
  • [18] Selective BET Protein Inhibition with Apabetalone and Cardiovascular Events: A Pooled Analysis of Trials in Patients with Coronary Artery Disease
    Stephen J. Nicholls
    Kausik K. Ray
    Jan O. Johansson
    Alan Gordon
    Michael Sweeney
    Chris Halliday
    Ewelina Kulikowski
    Norman Wong
    Susan W. Kim
    Gregory G. Schwartz
    [J]. American Journal of Cardiovascular Drugs, 2018, 18 : 109 - 115
  • [19] Effect of BET Protein Inhibition With Apabetalone on Cardiovascular Outcomes in Patients With Acute Coronary Syndrome and Diabetes - Results of the BETonMACE Trial
    Ray, Kausik K.
    Nicholls, Stephen J.
    Ginsberg, Henry N.
    Johansson, Jan O.
    Kalantar-Zadeh, Kamyar
    Kulikowski, Ewelina
    Toth, Peter P.
    Wong, Norman
    Sweeney, Michael
    Schwartz, Gregory G.
    [J]. CIRCULATION, 2019, 140 (25) : E966 - E966
  • [20] The BET protein inhibitor apabetalone (RVX-208) restores angiogenic response in type 1 and type 2 diabetes by transcriptional regulation of thrombospondin-1
    Mohammed, S.
    Mattia, M. A.
    Gergely, G. K.
    Gaia, G. S.
    Ambrosini, S. A.
    Paolo, P. M.
    Thomas, T. F. L. F.
    Sarah, S. C.
    Paolo, G. P. F. Gian
    Francesco, F. P.
    [J]. EUROPEAN HEART JOURNAL, 2021, 42 : 3384 - 3384
12345